EKF Diagnostics Holdings ( (GB:EKF) ) has issued an announcement.
EKF Diagnostics Holdings plc has announced a share buyback, acquiring 141,693 ordinary shares at a price of 22.5 pence each, which will be held in treasury. This move is part of a broader strategy to manage the company’s share capital and maintain shareholder value. The transaction included the purchase of shares from Harwood as investment manager to Oryx, ensuring that Mr. Mills’ indirect beneficial interest remains stable. Following this buyback, the total number of shares with voting rights stands at 452,888,871. This strategic financial maneuver is expected to impact the company’s market positioning by potentially enhancing shareholder value and maintaining control over share distribution.
More about EKF Diagnostics Holdings
EKF Diagnostics Holdings plc is an AIM-listed global diagnostics business that specializes in point-of-care analyzers, particularly in hematology and diabetes. The company also provides life sciences services, manufacturing specialist enzymes and custom products for diagnostic, food, and industrial applications. Headquartered in Penarth, near Cardiff, EKF operates five manufacturing sites across the US and Germany and sells its products in over 120 countries worldwide.
YTD Price Performance: -14.81%
Average Trading Volume: 524,242
Technical Sentiment Signal: Buy
Current Market Cap: £99.82M
See more data about EKF stock on TipRanks’ Stock Analysis page.